Literature DB >> 28921728

Undifferentiated connective tissue diseases and adverse pregnancy outcomes. An undervalued association?

Arsenio Spinillo1, Fausta Beneventi1, Roberto Caporali2, Veronique Ramoni2, Carlomaurizio Montecucco2.   

Abstract

Undifferentiated connective tissue diseases (UCTDs) are a heterogeneous group of disorders characterized by symptoms and signs suggestive of systemic autoimmune rheumatic disease (ARD), but which do not fulfill all the established criteria for definite diagnosis of a condition. Although a third of UCTDs can progress to a definite ARD within months or years, most UCTDs can remain stable for years with minimal disease activity. The annual incidence of UCTD in the general population ranges from 14 to 140 per 100 000 people. UCTDs are associated with the persistence of several circulating autoantibodies including antinuclear, antiphospholipid or antithyroid antibodies. Immunological evaluation of subjects with UCTDs suggests a proinflammatory state and dysregulation of the Th1/Th2 balance. Autoantibodies have well-known deleterious effects on placentation and have been associated with an increased risk of prematurity, fetal growth restriction (FGR), preeclampsia, and congenital atrioventricular heart block. Although epidemiological and biological data suggest a potential negative impact on reproductive outcomes, the relationship between UCTD and pregnancy outcomes has not been adequately studied. While awaiting definitive data from large studies, obstetricians should be aware that rheumatic disorders in their early, incomplete, or undifferentiated phases can adversely affect pregnancy outcomes, increasing the likelihood of pregnancy loss, FGR, preeclampsia, and prematurity.
© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  autoimmune systemic diseases; fetal growth restriction; pregnancy; prematurity; rheumatic diseases; undifferentiated connective tissue diseases

Mesh:

Substances:

Year:  2017        PMID: 28921728     DOI: 10.1111/aji.12762

Source DB:  PubMed          Journal:  Am J Reprod Immunol        ISSN: 1046-7408            Impact factor:   3.886


  3 in total

1.  A three-arm, multicenter, open-label randomized controlled trial of hydroxychloroquine and low-dose prednisone to treat recurrent pregnancy loss in women with undifferentiated connective tissue diseases: protocol for the Immunosuppressant regimens for LIving FEtuses (ILIFE) trial.

Authors:  Shaoying Yang; Ruoning Ni; Yikang Lu; Suli Wang; Feng Xie; Chunyan Zhang; Liangjing Lu
Journal:  Trials       Date:  2020-09-09       Impact factor: 2.279

2.  Pregnancy outcomes in women with idiopathic inflammatory myopathy, before and after diagnosis-a population-based study.

Authors:  Weng Ian Che; Karin Hellgren; Olof Stephansson; Ingrid E Lundberg; Marie Holmqvist
Journal:  Rheumatology (Oxford)       Date:  2020-09-01       Impact factor: 7.580

Review 3.  Undifferentiated Connective Tissue Disease in Pregnancy: A Topic Yet to be Explored.

Authors:  Caterina Serena; Sara Clemenza; Serena Simeone; Sara Zullino; Serena Ottanelli; Marianna Pina Rambaldi; Silvia Vannuccini; Felice Petraglia; Federico Mecacci
Journal:  Front Pharmacol       Date:  2022-01-20       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.